MedTrace Logo

A Study of RTA 402 in Obese Adults

NCT04018339 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-06-23

No results posted yet for this study

Summary

To investigate changes in body weight and body composition in obese adults after repeated oral administration of RTA 402 once daily for 16 weeks, using placebo as a control.

Conditions

  • Obese Adult Male

Interventions

DRUG

Bardoxolone methyl

Bardoxolone methyl 5 mg capsules

DRUG

Placebo

Capsules containing an inert placebo

Sponsors & Collaborators

  • Kyowa Kirin Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
49 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-20
Primary Completion
2020-05-28
Completion
2020-06-18

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04018339 on ClinicalTrials.gov